Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1982 Jun;13(1):5–13. doi: 10.1007/BF00200194

Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor

Timothy J Eberlein 1,✉, Maury Rosenstein 1, Paul Spiess 1, Robert Wesley 2, Steven A Rosenberg 1,2
PMCID: PMC11039233  PMID: 6984355

Abstract

Recently techniques have been developed for the long-term growth of cytotoxic T-lymphoid cells in vitro with T cell growth factor (TCGF). We have investigated the use of these in vitro-expanded T cells for the immunotherapy of a disseminated syngeneic murine FBL-3 lymphoma. In this model, mice with disseminated tumor were treated on day 5 with 180 mg cytoxan/kg and then 5 h later were given lymphoid cells IP. In vivo-immunized lymphocytes resulted in significantly improved survival in three of three experiments, curing 52% of 38 animals, compared with treatment with cytoxan alone (0 of 31 cured) or cytoxan plus unimmunized cells (0 of 40 cured) (P<0.0005). In vivo-immunized lymphocytes were re-exposed to FBL-3 tumor in vitro for 5 days in complete medium (CM) or lectin-free TCGF (LF-TCGF). Both groups showed significantly improved survival in six of six experiments. Cytoxan cured 17% of 66 animals, while cytoxan plus normal lymphocytes after IVS cured 6% of 47 animals. In vivo-immunized cells resensitized in vitro to FBL-3 in CM or LF-TCGF cured 82% of 50 animals (P<0.001) and 72% of 61 animals (P<0.001), respectively. Cells from in vivo- and in vitro-sensitized lymphocytes exhibited no cytotoxicity in our in vitro 51Cr-release assay; expansion of these cells resulted in significant specific lysis of fresh FBL-3 targets. Adoptive transfer of immune lymphocytes resensitized to FBL-3 tumor in vitro and expanded in LF-TCGF conferred a significant survival benefit (P<0.001, curing 7 of 27 animals) compared with all controls. These expanded cells were then continuously grown in LF-TCGF for 2 1/2 months. Again, in vivo-immunized lymphocytes resensitized to FBL-3 tumor and expanded in LF-TCGF for 2 1/2 months cured 56% of the animals with disseminated tumor, significantly prolonging survival over that recorded in any control group (P<0.0002). Irradiation of these same cells totally abolished their efficacy. Clones were generated from IVS and continuously grown in LF-TCGF. Two of these clones were very cytotoxic for fresh FBL-3 (>4,000 lytic units/106 cells). When adoptively transferred to mice in this chemoimmunotherapy model these cytotoxic clones significantly enhanced survival over that recorded following treatment with cytoxan alone (P<0.00001), though prolongation of survival was small. Implications of these results for application of these techniques to other less antigenic tumors and human cancers are discussed.

Keywords: Lymphoma, Complete Medium, Lymphoid Cell, Antigenic Tumor, Adoptive Transfer

References

  • 1.Alaba O, Bernstein ID. Tumor-growth suppression in vivo: Cooperation between immune lymphoid cells sensitized in vitro and nonimmune bone marrow cells. J Immunol. 1978;120:1941. [PubMed] [Google Scholar]
  • 2.Baker PE, Gillis S, Fern MM, Smith KA. The effect of T-cell growth factor on the generation of cytotoxic T cells. J Immunol. 1978;121:2168. [PubMed] [Google Scholar]
  • 3.Baker PE, Gillis S, Smith KA. Monoclonal cytolytic T-cell lines. J Exp Med. 1979;149:273. doi: 10.1084/jem.149.1.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Berenson JR, Einstein AB, Jr, Fefer A. Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: Requirement for T cells. J Immunol. 1975;115:236. [PubMed] [Google Scholar]
  • 5.Bernstein ID. Passive transfer of systemic tumor immunity with cells generated in vitro by a secondary immune response to a syngeneic rat Gross virus-induced lymphoma. J Immunol. 1977;118:122. [PubMed] [Google Scholar]
  • 6.Borberg H, Oettgen HF, Choudry K, Beattie EJ., Jr Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors. Int J Cancer. 1972;10:539. doi: 10.1002/ijc.2910100312. [DOI] [PubMed] [Google Scholar]
  • 7.Cheever MA, Kempf RA, Fefer A. Tumor neutralization, immunotherapy and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro. J Immunol. 1977;119:714. [PubMed] [Google Scholar]
  • 8.Cheever MA, Greenberg PD, Fefer A. Tumor neutralization, immunotherapy and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro. II. J Immunol. 1978;121:2220. [PubMed] [Google Scholar]
  • 9.Cheever MA, Greenberg PD, Fefer A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol. 1980;125:711. [PubMed] [Google Scholar]
  • 10.Cheever MA, Greenberg PD, Fefer A. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with interleukin 2. J Immunol. 1981;126:1318. [PubMed] [Google Scholar]
  • 11.Fass L, Fefer A. Factors related to therapeutic efficacy on adoptive chemoimmunotherapy of a Friend virus-induced lymphoma. Cancer Res. 1972;32:2427. [PubMed] [Google Scholar]
  • 12.Fass L, Fefer A. Studies of adoptive chemoimmunotherapy of a Friend virus-induced lymphoma. Cancer Res. 1972;32:997. [PubMed] [Google Scholar]
  • 13.Fefer A, Einstein AB, Jr, Cheever MA. Adoptive chemoimmunotherapy of cancer in animals: A review of results, principles and problems. Ann NY Acad Sci. 1976;277:492. doi: 10.1111/j.1749-6632.1976.tb41723.x. [DOI] [PubMed] [Google Scholar]
  • 14.Fefer A, Einstein AB, Jr, Cheever MA, Berenson JR. Models for syngeneic adoptive chemoimmunotherapy of murine leukemias. Ann NY Acad Sci. 1976;276:573. doi: 10.1111/j.1749-6632.1976.tb41684.x. [DOI] [PubMed] [Google Scholar]
  • 15.Fernandez-Cruz E, Halliburton B, Feldman J. In vivo elimination by specific effector cells of an established syngeneic rat Moloney virus-induced sarcoma. J Immunol. 1979;123:1772. [PubMed] [Google Scholar]
  • 16.Fernandez-Cruz E, Woda BA, Feldman JD. Elimination of syngeneic sarcomas in rats by a subset of T-lymphocytes. J Exp Med. 1980;152:823. doi: 10.1084/jem.152.4.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Freedman LR, Cerottini JC, Brunner KT. In vivo studies of the role of cytotoxic T-cells in tumor allograft immunity. J Immunol. 1972;109:1371. [PubMed] [Google Scholar]
  • 18.Gillis S, Smith KA. Long-term culture of tumor-specific cytotoxic T cells. Nature. 1977;268:154. doi: 10.1038/268154a0. [DOI] [PubMed] [Google Scholar]
  • 19.Glynn JP, McCoy JL, Fefer A. Cross-resistance to the transplantation of syngeneic Friend, Moloney and Rauscher virus-induced tumors. Cancer Res. 1968;28:434. [PubMed] [Google Scholar]
  • 20.Greenberg PD, Cheever MA, Fefer A. Detection of early and delayed anti-tumor effects following curative adoptive chemoimmunotherapy of established leukemia. Cancer Res. 1980;40:4426. [PubMed] [Google Scholar]
  • 21.Kedar E, Raanan Z, Schwartzbach M. In vitro induction of cell-mediated immunity to murine leukemia cells. VI. Adoptive immunotherapy in combination with chemotherapy of leukemia in mice using lymphocytes sensitized in vitro to leukemia cells. Cancer Immunol Immunother. 1978;4:161. [Google Scholar]
  • 22.Lotze MT, Line BR, Mathisen DJ, Rosenberg SA. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): Implications for the adoptive immunotherapy of tumors. J Immunol. 1980;125:1487. [PubMed] [Google Scholar]
  • 23.Loveland BE, Hogarth PM, Ceredig RH, McKenzie IFC. Cells mediating graft rejection in the mouse. I. Lyt-l cells mediate skin graft rejections. J Exp Med. 1981;152:1044. doi: 10.1084/jem.153.5.1044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Matter A, Askonas BA. Protection against murine ascites tumours by lymphoid cell populations with T-memory or cytotoxicity. Transplantation. 1976;22:184. doi: 10.1097/00007890-197608000-00014. [DOI] [PubMed] [Google Scholar]
  • 25.Mills GB, Paetkau V. Generation of cytotoxic lymphocytes to syngeneic tumor by using co-stimulator (interleukin 2) J Immunol. 1980;125:1897. [PubMed] [Google Scholar]
  • 26.Parker GA, Rosenberg SA. Serologic identification of multiple tumor-associated antigens on murine sarcoma. J Natl Cancer Inst. 1977;58:1303. doi: 10.1093/jnci/58.5.1303. [DOI] [PubMed] [Google Scholar]
  • 27.Peto R, Pike M, Armitage P, Breslow N, Cox D, Howard S, Mantel N, McPherson K, Peto J, Smith P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977;35:1. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Reyser J, Cerottini J, Brunner KT. Cell-mediated immunity to antigens associated with murine sarcoma virus-induced tumors: Augmentation of cytolytic T-lymphocyte activity by successive specific and non-specific stimulation in vitro. Eur J Immunol. 1979;9:179. doi: 10.1002/eji.1830090302. [DOI] [PubMed] [Google Scholar]
  • 29.Rollinghoff M, Wagner H. Brief communication: In vivo protection against murine plasma cell tumor growth by in vitro activated syngeneic lymphocytes. J Natl Cancer Inst. 1973;51:1317. doi: 10.1093/jnci/51.4.1317. [DOI] [PubMed] [Google Scholar]
  • 30.Rosenberg SA, Terry WD. Passive immunotherapy of cancer in animals and man. Adv Cancer Res. 1977;25:323. doi: 10.1016/s0065-230x(08)60637-5. [DOI] [PubMed] [Google Scholar]
  • 31.Rosenberg SA, Schwarz S, Spiess PJ. In vitro growth of murine T cells. II. growth of in vitro sensitized cells cytotoxic for alloantigens. J Immunol. 1978;121:1951. [PubMed] [Google Scholar]
  • 32.Rosenberg SA, Schwarz S, Spiess PJ, Brown JM. In vitro growth of murine T cells. III. Method for separation of T-cell growth factor (TCGF) from Conconavalin A and biological activity of the resulting TCGF. J Immunol Methods. 1980;33:337. doi: 10.1016/0022-1759(80)90004-6. [DOI] [PubMed] [Google Scholar]
  • 33.Rosenberg SA, Spiess PJ, Schwarz S. In vitro growth of murine T cells. IV. Use of T cell growth factor (TCGF) to clone lymphoid cells. Cell Immunol. 1980;54:293. doi: 10.1016/0008-8749(80)90211-7. [DOI] [PubMed] [Google Scholar]
  • 34.Roseneau W, Morton DL. Tumor-specific inhibition of growth of methylcholanthrene-induced sarcoma in vivo and in vitro by sensitized isologous lymphoid cells. J Natl Cancer Inst. 1966;36:825. [Google Scholar]
  • 35.Rosenstein M, Eberlein TJ, Kemeny MM, Sugarbaker PH, Rosenberg SA. In vitro growth of murine T-cells. VI. Accelerated skin graft rejection caused by adoptively transferred cells expanded in T cell growth factor. J Immunol. 1981;127:566. [PubMed] [Google Scholar]
  • 36.Rouse BT, Rollinghoff M, Warner NL. Tumor immunity to murine plasma cell tumors. II. Essential role of T lymphocytes in immune response. Eur J Immunol. 1973;3:318. doi: 10.1002/eji.1830030408. [DOI] [PubMed] [Google Scholar]
  • 37.Small M, Trainin N. Inhibition of syngeneic fibrosarcoma growth by lymphocytes sensitized on tumor-cell monolayers in the presence of the thymic humoral factor. Int J Cancer. 1975;15:962. doi: 10.1002/ijc.2910150612. [DOI] [PubMed] [Google Scholar]
  • 38.Smith HG, Harmel RP, Hanna MG, Jr, Zwilling BS, Zbar B, Rapp HJ. Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune cells. J Natl Cancer Inst. 1977;58:1315. doi: 10.1093/jnci/58.5.1315. [DOI] [PubMed] [Google Scholar]
  • 39.Smith KA, Gillis S, Baker P. The inhibition of in vivo tumor growth by cytotoxic T-cell lines. Proc Am Assoc Cancer Res. 1979;20:93. [Google Scholar]
  • 40.Smith KA, Baker PE, Gillis S, Ruscetti FW. Functional and molecular characteristics of T-cell growth factor. Mol Immunol. 1980;17:579. doi: 10.1016/0161-5890(80)90156-x. [DOI] [PubMed] [Google Scholar]
  • 41.Spiess PJ, Rosenberg SA. A simplified method for the production of murine T-cell growth factor free of lectin. J Immunol Methods. 1981;42:213. doi: 10.1016/0022-1759(81)90151-4. [DOI] [PubMed] [Google Scholar]
  • 42.Tevethia SS, Blasecki JW, Waneck G, Goldstein AL. Requirement of thymus-derived theta-positive lymphocytes for rejection of DNA virus (SV40) tumors in mice. J Immunol. 1974;113:1417. [PubMed] [Google Scholar]
  • 43.Treves AJ, Cohen IR, Feldman M. Immunotherapy of lethal metastases by lymphocytes sensitized against tumor cells in vitro. J Natl Cancer Inst. 1975;54:777. [PubMed] [Google Scholar]
  • 44.Treves AJ, Cohen IR, Schechter B, Feldman M. In vivo effects of lymphocytes sensitized in vitro against tumor cells. Ann NY Acad Sci. 1976;276:165. doi: 10.1111/j.1749-6632.1976.tb41644.x. [DOI] [PubMed] [Google Scholar]
  • 45.Vadlamudi S, Padarathsingh M, BonMassar E, Goldin A. Effect of combination treatment with cyclophosphamide and isogeneic or allogeneic spleen and bone marrow cells in leukemic (L1210) mice. Int J Cancer. 1971;7:160. doi: 10.1002/ijc.2910070118. [DOI] [PubMed] [Google Scholar]
  • 46.Vasudevan DM, Brunner KT, Ceottini JC. Detection of cytotoxic T lymphocytes in the E14 mouse leukemia system: Increased activity of immune spleen and peritoneal cells following preincubation and cell fractionation procedures. Int J Cancer. 1974;14:301. doi: 10.1002/ijc.2910140303. [DOI] [PubMed] [Google Scholar]
  • 47.Watson J. Continuous proliferation of murine antigen-specific helper T-lymphocytes in culture. J Exp Med. 1979;150:1510. doi: 10.1084/jem.150.6.1510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Wepsic HT, Kronman BS, Zbar B, Borsos T, Rapp HJ. Immunotherapy of an intramuscular tumor in strain-2 guinea pigs: Prevention of tumor growth by intradermal immunization and by systemic transfer of tumor immunity. J Natl Cancer Inst. 1970;45:377. [PubMed] [Google Scholar]
  • 49.Zarling JM, Tevethia SS. Transplantation immunity to Simian virus-40-transformed cells in tumor-bearing mice. I. Development of cellular immunity to Simian virus 40 tumor-specific transplantation antigens during tumorigenesis by transplanted cells. J Natl Cancer Inst. 1973;50:137. doi: 10.1093/jnci/50.1.137. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES